Cannara Biotech reveals plan for settlement of convertible debenture
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2025
0mins
Should l Buy ?
Debt Settlement Announcement: Cannara Biotech plans to settle approximately $6.2M in debt, which includes $4.7M in principal and $1.5M in accrued interest, related to its convertible debenture with Olymbec Investments.
Share Issuance for Debt Repayment: The company intends to repay the outstanding debt by issuing 3,462,763 common shares at a deemed price of $1.80 per share, with 851,652 shares allocated for interest repayment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
